Open Orphan #ORPH / hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model October 20, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies, is pleased to announce the signing of a contract by hVIVO, a subsidiary of Open Orphan, with the UK Government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus.…

Continue reading

Open Orphan #ORPH – Statement re further media comment on UK Government and other partners for a UK Coronavirus challenge study October 16, 2020 – Posted in: Open Orphan (ORPH)

Further to our announcement of 24 September 2020 and further media comment the Company confirms that it remains in advanced negotiations with the UK Government and other partners for a Coronavirus challenge study in the UK. No contract has been signed and the Company will update the market in due course as appropriate. For further information please contact   Open Orphan plc +353 (0)1 644 0007   Cathal Friel, Executive Chairman   Arden Partners plc…

Continue reading

Open Orphan #ORPH – Statement re price movement and press speculation September 24, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials notes the recent share price movement and press speculation regarding UK government-funded Coronavirus human challenge studies. The Company confirms that it is in advanced negotiation with the UK Government and other partners for a Coronavirus challenge study in the UK. While negotiations continue, it is expected…

Continue reading